StreetInsider.com News Articles

Roche gets FDA clearance for two new laboratory analytical units

Mon, 30 Mar 2026 09:01:32 -0400

Roche (Swiss: RO) announced that the U.S. Food and Drug Administration granted 510(k) clearance for its cobas c703 and cobas ISE neo analytical units on March 30, 2026.

The cobas c703 analytical unit processes up to 2,000 tests per hour and includes 70 reagent positions. The unit doubles clinical chemistry throughput compared to previous systems and requires monthly operator maintenance.

The cobas ISE neo analytical unit delivers up to 1,800 tests per hour and features automated maintenance capabilities. The system produces more tests per reagent bottle compared to earlier generation systems.

Both units are part of Roche's cobas pro integrated solutions platform, which

Roche gets FDA clearance for two new laboratory analytical units

Mon, 30 Mar 2026 09:01:32 -0400

Roche (Swiss: RO) announced that the U.S. Food and Drug Administration granted 510(k) clearance for its cobas c703 and cobas ISE neo analytical units on March 30, 2026.

Both units are part of Roche's cobas pro integrated solutions platform, which

Roche gets FDA clearance for two new laboratory analytical units

Mon, 30 Mar 2026 09:01:32 -0400

Roche (Swiss: RO) announced that the U.S. Food and Drug Administration granted 510(k) clearance for its cobas c703 and cobas ISE neo analytical units on March 30, 2026.

Both units are part of Roche's cobas pro integrated solutions platform, which

Roche gets FDA clearance for two new laboratory analytical units

Mon, 30 Mar 2026 09:01:32 -0400

Roche (Swiss: RO) announced that the U.S. Food and Drug Administration granted 510(k) clearance for its cobas c703 and cobas ISE neo analytical units on March 30, 2026.

Both units are part of Roche's cobas pro integrated solutions platform, which

Roche gets FDA clearance for two new laboratory analytical units

Mon, 30 Mar 2026 09:01:32 -0400

Roche (Swiss: RO) announced that the U.S. Food and Drug Administration granted 510(k) clearance for its cobas c703 and cobas ISE neo analytical units on March 30, 2026.

Both units are part of Roche's cobas pro integrated solutions platform, which

Roche gets FDA clearance for two new laboratory analytical units

Mon, 30 Mar 2026 09:01:32 -0400

Roche (Swiss: RO) announced that the U.S. Food and Drug Administration granted 510(k) clearance for its cobas c703 and cobas ISE neo analytical units on March 30, 2026.

Both units are part of Roche's cobas pro integrated solutions platform, which

Roche gets FDA clearance for two new laboratory analytical units

Mon, 30 Mar 2026 09:01:32 -0400

Roche (Swiss: RO) announced that the U.S. Food and Drug Administration granted 510(k) clearance for its cobas c703 and cobas ISE neo analytical units on March 30, 2026.

Both units are part of Roche's cobas pro integrated solutions platform, which

Roche gets FDA clearance for two new laboratory analytical units

Mon, 30 Mar 2026 09:01:32 -0400

Roche (Swiss: RO) announced that the U.S. Food and Drug Administration granted 510(k) clearance for its cobas c703 and cobas ISE neo analytical units on March 30, 2026.

Both units are part of Roche's cobas pro integrated solutions platform, which

Roche gets FDA clearance for two new laboratory analytical units

Mon, 30 Mar 2026 09:01:32 -0400

Roche (Swiss: RO) announced that the U.S. Food and Drug Administration granted 510(k) clearance for its cobas c703 and cobas ISE neo analytical units on March 30, 2026.

Both units are part of Roche's cobas pro integrated solutions platform, which

Roche gets FDA clearance for two new laboratory analytical units

Mon, 30 Mar 2026 09:01:32 -0400

Roche (Swiss: RO) announced that the U.S. Food and Drug Administration granted 510(k) clearance for its cobas c703 and cobas ISE neo analytical units on March 30, 2026.

Both units are part of Roche's cobas pro integrated solutions platform, which

Roche gets FDA clearance for two new laboratory analytical units

Mon, 30 Mar 2026 09:01:32 -0400

Roche (Swiss: RO) announced that the U.S. Food and Drug Administration granted 510(k) clearance for its cobas c703 and cobas ISE neo analytical units on March 30, 2026.

Both units are part of Roche's cobas pro integrated solutions platform, which

Roche gets FDA clearance for two new laboratory analytical units

Mon, 30 Mar 2026 09:01:32 -0400

Roche (Swiss: RO) announced that the U.S. Food and Drug Administration granted 510(k) clearance for its cobas c703 and cobas ISE neo analytical units on March 30, 2026.

Both units are part of Roche's cobas pro integrated solutions platform, which

Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories

Mon, 30 Mar 2026 09:00:00 -0400

The cobas® c 703 and cobas® ISE neo analytical units deliver higher testing capacity and increased automation, helping to improve laboratory workflows and advance patient care.
High-throughput efficiency, with up to 2,000 tests per hour on cobas® c 703 and up to 70 reagent positions for testing optimization.
The new cobas® ISE neo analytical unit delivers up to 1,800 tests per hour and reduces hands-on time through automated maintenance.